Kornimate/medical-research-clean huggingface dataset:
evaluation of the review of automated ventilator data's effect on the incidence of ventilator associated events in a medical surgical intensive care unit

Conditions: Ventilator Associated Events

Summary: this study will be a retrospective, observational analysis study of ventilator patients in the medical surgical intensive care unit being monitored via automated near real-time ventilator analytical software.

this study will be a retrospective review of data via chart review of all mechanically ventilated patients in an intensive care unit meeting our inclusion criteria during the pre-implementation and post-implementation phases of the study. data will be collected and a detailed analysis of outcomes will be performed. the major parameters that will be measured will focus on the rate of ventilator associated events during each phases of the analysis. ventilator associated events will be defined as ventilator associated conditions (vacs), infection related ventilator associated conditions (ivacs) and probable ventilator associated pneumonias (pvaps). according to the center for disease \& control a vac occurs after a patients has ≥ 2 days of stable or decreasing minimum fio2 or peep values and then experiences at least one of the following: increased in the daily minimum fio2 of ≥ 0.20 over the daily minimum fio2 in the baseline period, sustained for ≥ 2 calendar days or increase in the daily minimum peep values of ≥ 3 cmh2o over the daily minimum peep in the baseline period sustained for ≥ 2 calendar days. an ivac is defined as the occurrence on or after calendar day 3 of mechanical ventilation and within 2 calendar days before or after the onset of worsening oxygenation, the patient meets both of the following criteria: 1) temperature \> 38c, or white blood cell count ≥ 12,000 cells/mm3 or ≤ 4,000 cells/mm3 and a new antimicrobial agents(s) is started for ≥ 4 calendar days. a pvap is occurs when a patient meets the criteria for a vac and ivac and one of the following criteria are met: 1) purulent respiratory secretions (from one or more specimen collections). 2) positive culture (qualitative, semi-quantitative) of sputum, endotracheal aspirate, bronchoalveolar lavage, lung tissue, or protected specimen brushing.

Eligibility criteria:
inclusion criteria: * includes all mechanically ventilated patients in the intensive care unit above the age of 18 years of age and who were mechanically ventilated for ≥ 3 days. exclusion criteria: * any patients under the age of 18 or mechanically ventilated for \< 3days.

Keywords: ventilator associated conditions infection related ventilator associated conditions probable ventilator associated pneumonia
the nor-switch study

Conditions: Rheumatoid Arthritis; Spondyloarthritis; Psoriatic Arthritis; Ulcerative Colitis; Crohn's Disease; Psoriasis Chronic

Summary: the purpose of this study is to assess the safety and efficacy of switching from remicade to the biosimilar treatment remsima in patients with rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, crohn's disease and chronic plaque psoriasis


Eligibility criteria:
inclusion criteria: 1. a clinical diagnosis of either rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, crohn's disease or chronic plaque psoriasis 2. male or non-pregnant, non-nursing female 3. \>18 years of age at screening 4. stable treatment with innovator infliximab (remicade) during the last 6 months 5. subject capable of understanding and signing an informed consent form 6. provision of written informed consent exclusion criteria: 1. major co-morbidities, such as severe malignancies, severe diabetic mellitus, severe infections, uncontrollable hypertension, severe cardiovascular disease (nyha class 3 or 4) and/or severe respiratory diseases 2. change of major co-medication during the last 2 months prior to randomization: ra, spa and psa: initiation of systemic corticosteroids or synthetic dmards or other medication which according to the investigator would interfere with the stability of the disease. uc and cd: initiation of systemic corticosteroids or an immunosuppressant or other medication which according to the investigator would interfere with the stability of the disease psoriasis: initiation of synthetic dmards or other medication which according to the investigator would interfere with the stability of the disease 3. inadequate birth control, pregnancy, and/or breastfeeding 4. psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol impossible 5. change in treatment with innovator infliximab (remicade) during the last 6 months due to disease related factors, not including dose/frequency adjustments due to drug concentration measurements
a study of mk-5720 in participants with schizophrenia (mk-5720-001)

Conditions: Schizophrenia

Summary: the purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (pk) of single ascending intramuscular doses of mk-5720, and the safety and tolerability of multiple once-daily oral doses of mk-8189, in participants with schizophrenia. the primary study hypothesis is that the administration of mk-5720 is safe and well tolerated.

in period 1, participants receive once-daily mk-8189 for 7 days, followed by a 72-hour washout. in period 2, participants receive a single dose of mk-5720.

Eligibility criteria:
inclusion criteria: the main inclusion criteria include but are not limited to the following: * meets diagnostic criteria for schizophrenia or schizoaffective disorder according to the diagnostic and statistical manual of mental disorders, 5th edition (dsm-5) criteria with the onset of the first episode being no less than 2 years prior to screening and monotherapy with antipsychotics for treatment should be indicated * has a history of receiving and tolerating antipsychotics medication within the usual dose range employed for schizophrenia * can discontinue the use of all antipsychotic medication at least 5 days or 3 half-lives (which ever in longer) prior to the start of the treatment period and during the study exclusion criteria: the main exclusion criteria include but are not limited to the following: * is at imminent risk of self-harm, based on clinical interview and responses on the columbia-suicide severity rating scale (c-ssrs), or of harm to others in the opinion of the investigator * has history of mental retardation, borderline personality disorder, or organic brain syndrome * has a history of neuroleptic malignant syndrome or moderate to severe tardive dyskinesia * has a substance-induced psychotic disorder or behavioral disturbance thought to be due to substance abuse * has a history of seizure disorder beyond childhood or is receiving treatment with any anticonvulsant to prevent seizures * has a family history of sudden death * has claustrophobia to a degree that prevents tolerance of magnetic resonance imaging (mri) scanning procedure * has a metallic implant of any sort that prevents mri examination, or any other contraindication to mri examination * presents any concern by the investigator regarding safe participation in the study or for any other reason the investigator considers the participant inappropriate for participation in the study * history of significant multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food * positive test(s) for hepatitis b surface antigen (hbsag), hepatitis c antibodies or human immunodeficiency virus (hiv) * has received or is currently receiving treatment with clozapine for any length of time * has received any live vaccines within 30 days prior to the first dose of study intervention or is scheduled to receive any live vaccine through 60 days following study intervention
a phase iii trial assessing the pharmacodynamic effect and the tolerability of grazax treatment

Conditions: Grass Pollen Allergy

Summary: the study assess the pharmacodynamic effect and the tolerability of grazax treatment initiated in the grass pollen season in subjects with seasonal grass pollen induced rhinoconjunctivitis


Eligibility criteria:
inclusion criteria: * positive skin prick test to phleum pratense * positive ige to phleum pratense * signed informed consent * a clinical history of moderate to severe persistent rhinoconjunctivitis symptoms exclusion criteria: * no uncontrolled asthma in the past 12 months * no history of an ige mediated systemic reaction due to food, insect venom, any kind of medication or induced by exercise, where there are symptoms both from the skin and the respiratory system with or without hypotension * no history of an ige mediated systemic reaction due to food, insect venom, any kind of medication or induced by exercise, where there are symptoms both from the skin and the respiratory system with or without hypotension
microbubbles and ultrasound in stroke trial: must study

Conditions: Acute Ischemic Stroke

Summary: to determine whether transcranial 2-mhz ultrasound combined with intravenous administration of microbubbles improves early recanalization in patients with acute ischemic stroke caused by middle cerebral artery (mca) proximal occlusion treated with intravenous alteplase within 3 hours of symptom onset.

proximal mca occlusion is recognized using mr or ct angiography performed before inclusion. all patients are treated with alteplase according to current guidelines. in addition, patients randomized in the active group are continuously exposed to transcranial 2-mhz ultrasound for 1 hour combined with intravenous administration of microbubbles. controls are only treated with alteplase. the ultrasound beam is positioned at the thrombus/blood flow interface using color-coded sonography. galactose-based microbubbles are administered via continuous intravenous infusion over 40 min. early recanalization is assessed using mr or ct angiography 4 to 8 hours after symptom onset. the evaluation of angiograms is performed by 2 neuroradiologists blinded to group of randomization and clinical details. the primary outcome measure is the rate of early recanalization. recanalization is assessed using the timi classification. secondary endpoints include the rate of symptomatic intracerebral hemorrhage, mortality, and functional outcome on the modified rankin scale at 3 months.

Eligibility criteria:
inclusion criteria: * acute ischemic stroke * mca proximal occlusion on ct or mr angiography * thrombolysis with intravenous alteplase initiated within 3 hours of stroke onset

Keywords: stroke thrombolysis ultrasound microbubbles alteplase
taste receptors regulation in cf patients

Conditions: Cystic Fibrosis

Summary: the project is intended to be realised in two phases. in the first stage, a case control study will be performed. in the second phase, double-blind, placebo controlled cross-over study will be conducted. the first stage it to compare innate immunity activation and pseudomonas aeruginosa (pa) expression between pa positive and negative patients. in the second phase the effects of inhaled lactizole- tas3r inhibitor will be assessed.

three visits have been planned during the entire study. during the first visit, all patients included in the study will have the following procedures: questionnaire tests, lung function tests, taste perception tests (gustometry) and exfoliative cytology of the nasal mucosa. patients with confirmed pseudomonas aeruginosa presence in the airways will be randomly assigned to the lactizole-placebo group and the placebo-lactizole group, with a recommendation to take laktizol (3 ml) for 3 weeks at the concentration determined during the preliminary examination, in the nebulization 2 times per day) or placebo (3ml 0.9% nacl solution in nebulization 2 once a day). the first nebulization of the solution issued during the visit will take place during the visit; each patient will undergo a clinical and spirometric assessment after 20 minutes of observation from completed nebulization. during the second visit (after 4 weeks from visit 1), the first visit procedures will be repeated for all patients. patients in the lactizole-placebo group will be recommended to take a placebo for 4 weeks (3 ml of 0.9% nacl solution in nebulization 2 once a day); on the other hand, patients from the placebo-lactizole group will be advised to take lactisol for 4 weeks (3 ml of the solution in the concentration determined during the preliminary examination, in the nebulization 2 once a day). the first nebulization of the solution issued during the visit will take place during the visit; each patient will undergo a clinical and spirometric assessment after 20 minutes of observation from completed nebulization. during the third visit (after 4 weeks from visit 2), the first visit procedures will be repeated for all patients.

Eligibility criteria:
inclusion criteria: * ulmonary manifestations of cystic fibrosis exclusion criteria: * first positive result of inoculation from the airways, which according to the standard is associated with the need for antibiotic therapy * contraindication to a biopsy of the nasal mucosa * exacerbation requiring antibiotics * diabetes, exposure to tobacco smoke * other chronic diseases and clinical conditions which, according to the researcher, may influence the assessed parameters and the course of the study. temporary exclusion criteria - acute respiratory infection within 2 weeks from 1, 2 and 3 visits of the study.
impact of three-dimensional visualization on operation strategy and complications for complex hepatic carcinoma

Conditions: Hepatic Carcinoma

Summary: the aim of the multi-centre study is to evaluate correctly the impact of three dimensional visualization on operation strategy and complications for complex hepatic carcinoma.

because of the complexity of complex hepatic carcinoma,the limitations of 2d images of ct/mri and the uncertainty of surgeons'experience, it is difficult for the surgeons to diagnosis and assess the operation strategy accurately based on traditional 2d imaging(ct/mri).the aim of the multi-centre study is to evaluate correctly the impact of three-dimensional visualization on operation strategy and complications for complex hepatic carcinoma.

Eligibility criteria:
inclusion criteria: 1. 18 years≤ age ≤70 years 2. compling with the diagnosis criteria of complex hepatic carcinoma. 3. primary hepatic carcinoma without intrahepatic or extrahepatic extensive cancer metastasis, the metastatic hepatic carcinoma whose primary focal has been controlled 4. preoperative liver function is child - pugh grade a or b. 5. the patients are volunteered for the study. exclusion criteria: 1. patients with mental illness. 2. patients can't tolerate the operation owe to a variety of basic diseases (such as severe cardiopulmonary insufficiency, renal insufficiency, cachexia and blood system diseases, etc.) 3. the patients refused to take part in the study. 4. there are other co-existed malignant tumors. 5. benign liver diseases.

Keywords: hepatic carcinoma,three-dimensional visualization
the role of daily disposable contact lenses in ocular allergy

Conditions: Grass Pollen Ocular Allergy

Summary: patients with seasonal allergic conjunctivitis are normally advised to avoid contact lens wear when they are having symptoms. however, modern soft contact lenses which are disposed of daily offer the potential to protect and lubricate the ocular surface. this study examines this possible effect.


Eligibility criteria:
inclusion criteria: * contact lens wearer * proven allergy to grass pollen exclusion criteria: * eye disease * ocular medication * allergy medication * asthma

Keywords: allergic conjunctivitis
global postural reeducation and segmental exercises in patients with scapular dyskinesis and cervicalgia

Conditions: Scapular Dyskinesis; Cervicalgia

Summary: the purpose of this study is to assess the effectiveness of global postural reeducation relative to segmental exercises in the treatment of scapular dyskinesis with cervicalgia.

purpose: to assess the effectiveness of global postural reeducation relative to segmental exercises in the treatment of scapular dyskinesis with cervicalgia. methods: participants with scapular dyskinesis and cervicalgia (n = 30) aged 18 to 65 years were randomly assigned to one of two groups: global postural reeducation and segmental exercises(stretching and strengthening). upper extremity was assessed using the disabilities of the arm, shoulder and hand (dash) questionnaire. function of the neck was estimated using the neck disability index (ndi). pain severity was measured using a visual analogical scale. health-related quality of life (hrqol) was assessed using the short form (sf)-12. assessments were conducted at baseline and after 10 weekly sessions (60 minutes each). significance level was established at 5%.

Eligibility criteria:
inclusion criteria: * scapular dyskinesis as per the sick scapula rating scale * chronic cervicalgia (pain for at least three months) exclusion criteria: * cervical stenosis * myelopathy * prolapsed inter-vertebral disk (as confirmed by magnetic resonance imaging), * winged scapula due to lesions of the long thoracic nerve or spinal accessory nerve, (as documented by electromyography)

Keywords: physical therapy modalities posture muscle stretching exercises dyskinesias neck pain
sequential vs. monophasic media impact trial (summit)

Conditions: Infertility

Summary: to evaluate the impact of two fda approved culture media on potential of human embryos resulting from ivf (sequential \& monophasic media). half of each patient's embryos will be randomly assigned to grow in monophasic media \& the other half in sequential media. all embryos will undergo comprehensive chromosome screening (ccs) \& the best euploid embryo from each group will be transferred resulting in a double embryo transfer (det). if there are only euploid embryos from one group, patient will have single embryo transfer (set)(fresh or frozen).


Eligibility criteria:
inclusion criteria: * patient undergoing ivf/ccs (no pgd banking) * patient meets asrm guidelines for double embryo transfer (det) * donor sperm ok * amh ≥ 1.2 * fsh ≤ 12 * bafc ≥12 * max 1 prior failed ivf cycle for patients 35-45 years old * patient \<35 years old must have 1 prior failed ivf cycle exclusion criteria: * chronic endometrial insufficiency * use of oocyte donor or gestational carriers * medical contraindications to double embryo transfer (det) * male factor (\<100,000 sperm or surgical sperm) * communicating hydrosalpinx (on hsg) * single gene disorders or sex selection

Keywords: monophasic sequential media
amcpr (augmented-medication cardiopulmonary resuscitation) trial for ohca

Conditions: Out-of-Hospital Cardiac Arrest

Summary: the investigators aimed to evaluate the effect of amcpr (augmented-medication cardiopulmonary resuscitation: administration of additional vasopressin to titrate to arterial diastolic blood pressure over 20 mmhg) on cardiopulmonary resuscitation results and outcomes in out-of-hospital cardiac arrest patients.

non-traumatic out-of-hospital cardiac arrest patients receive standard advanced cardiac life support according to the 2015 aha guideline, including chest compression, intubation, ventilation, defibrillation, drug administration, including epinephrine and antiarrhythmic drugs if indicated, in the emergency department. a research associate generates a random sequence using excel software, and assignment of participants to their respective groups will be undertaken by the principal investigator. arterial line insertion is performed within 6 minutes after randomization and diastolic blood pressure will be monitored. if diastolic blood pressure is \< 20 mmhg, drugs (vasopressin 40 iu or normal saline) will be administered for two times during cpr. arterial blood gas analysis will be analyzed for 5, 10, 15, and 20 minutes after arterial line insertion or termination of cpr. end-tidal carbon dioxide concentrations is monitored in real time during cpr and recorded every minute. the resuscitated patients receive standard post cardiac arrest care according to the 2015 aha guideline.

Eligibility criteria:
inclusion criteria: * non-traumatic adult out-of-hospital cardiac arrest (ohca) patients with non-shockable arrest rhythm exclusion criteria: * ohca with terminal illness documented by medical record, under hospice care, with pregnancy, with pre-documented 'do not resuscitate' card * trauma patients * age \< 18 years old * failed arterial line insertion within 6 minutes after randomization * extracorporeal cardiopulmonary resuscitation * time interval between arrest and ed arrival \> 60 minutes * rosc within 6 minutes after ed arrival * diastolic blood pressure \> 20 mmhg during resuscitation

Keywords: out-of-hospital cardiac arrest vasopressin
retrospective record review of adults and children advised for allergen immunotherapy (mk-7243-022)

Conditions: Perennial Allergic Rhinitis; Seasonal Allergic Rhinitis

Summary: the purpose of this study is to determine the proportion of participants that initiate allergen immunotherapy (ait) upon the recommendation of their physician and the proportion of participants that persist with their ait throughout the recommended course.


Eligibility criteria:
inclusion criteria: * diagnosis of ar with or without allergic conjunctivitis (ac) * documented provider-to-patient or parent discussion of ait as a treatment option exclusion criteria: * participants receiving ait as an ar treatment without documented provider-to-patient or parent discussion of ait as a treatment option * participants receiving immunotherapy for insect sensitivities only * ait started before 2005

Keywords: rhinitis allergen immunotherapy
brain imaging in the idiopathic rem sleep behavior disorder (alice)

Conditions: REM Sleep Behavior Disorder; Healthy

Summary: idiopathic rapid eye movement sleep behavior disorder (irbd) is characterized by nocturnal violence, increased muscle tone during rem sleep and the lack of any other neurological disease. however, irbd can precede parkinsonism and dementia by several years. the causes of the loss of muscle atonia during rem sleep in these patients are unclear. using 3 t mri and neuromelanin- sensitive sequences, the signal intensity was previously found to be reduce in the locus coeruleus/subcoeruleus area of patients with parkinson's disease and rbd. here, the investigators aimed at studying the integrity of the locus coeruleus/ subcoeruleus complex with neuromelanin-sensitive imaging in 21 patients with irbd and compared the results with those from 21 age- and gender-matched healthy volunteers. all subjects will undergo a clinical examination, motor, cognitive, autonomous, psychological, olfactory and color vision tests, and rapid eye movement sleep characterization using video-polysomnography and 3 t magnetic resonance imaging.


Eligibility criteria:
inclusion criteria: - idiopathic rbd (criteria of the international classification of sleep disorders-3) for healthy controls : no neurologic or psychiatric disorder exclusion criteria: * contraindication to mri * do not speak french